This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, regulatory events, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2021, there were 82,100 incident cases of Hodgkin’s lymphoma worldwide, and expects that number to increase to 86,500 incident cases by 2028.
• In the same year, there were approximately 281,800 five-year prevalent cases of Hodgkin’s lymphoma worldwide, which is expected to increase to 295,000 five-year prevalent cases by 2028.
• The approved drugs in the Hodgkin’s lymphoma space target antibody-drug conjugate, cluster of differentiation 30/TNFRSF8, microtubules (tubulin), DNA, the immune system, and programmed death-1 receptor/programmed death ligands (PD-L1 and PD-L2). The majority of the approved drugs are administered via the intravenous route.
• The majority of industry-sponsored drugs in active clinical development for Hodgkin’s lymphoma are in Phase II. Therapies in the pipeline for Hodgkin’s lymphoma focus on a variety of targets. These therapies are being tested in intravenous, subcutaneous, and intratumoral formulations.
• The overall likelihood of approval of a Phase I hematologic asset is 7.7%, and the average probability a drug advances from Phase III is 55.9%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.9 years in the overall oncology space.
• The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for Hodgkin’s lymphoma have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
• The US has a substantial lead in the number of Hodgkin’s lymphoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia. • Clinical trial activity in the Hodgkin’s lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin’s lymphoma, with 54 trials.
• Takeda leads industry sponsors with the highest overall number of clinical trials for Hodgkin’s lymphoma, followed by Bristol Myers Squibb.